Financial Performance - TG Therapeutics reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents [1] - The company reported sales of $120.86 million, up from $63.47 million a year ago, beating the consensus of $118.43 million [1] Product Performance - Briumvi's U.S. net sales reached $119.7 million, demonstrating growing confidence in the treatment and increasing adoption by healthcare providers [2][3] - The company presented five-year data from the ULTIMATE I & II Phase 3 trials, showing that 92% of patients were free from disability progression after five years, with an annualized relapse rate of 0.02 during year 5 [4] - No new safety signals emerged over five years of continuous treatment, with no observed cases of progressive multifocal leukoencephalopathy (PML) [4] Future Guidance - TG Therapeutics raised Briumvi's U.S. net product revenue target to $560 million for fiscal 2025 from $525 million in prior guidance [5] - The total global revenue target was raised to $575 million from prior guidance of $540 million [5] - Briumvi's U.S. net product revenue is expected to be $135 million in the second quarter of 2025 [5] Stock Performance - TGTX stock was down 13.2% at $37.68 on Monday [6]